IMPACT Therapeutics, Inc (HKG:7630)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Research, Development & Commercialisation of Pharmaceutical Products	38.25M	33.55M
Research, Development & Commercialisation of Pharmaceutical Products Growth	14.02%	-
Total	38.25M	33.55M
Total Growth	14.02%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Chinese Mainland	20.25M	-
USA	18.00M	33.55M
USA Growth	-46.33%	-
Total	38.25M	33.55M
Total Growth	14.02%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jun 21, 2026

Data Sources Report a data error